Table 3 Baseline echocardiographic parameters and changes from baseline to month 30 in the baseline tafamidis subgroup

From: Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial

Echocardiographic parameter

Baseline

LS mean change at month 30

Placebo-corrected treatment difference (95% CI)

N

Placebo (n = 129)

Vutrisiran (n = 130)

Placebo (n = 129)

Vutrisiran (n = 130)

LV structure

 Mean LV wall thickness (mm)

257

18.0 (2.4)

18.2 (2.6)

0.5 (0.2)

0.6 (0.2)

0.1 (−0.1, 0.6)

 LVEDD (mm)

255

42.8 (6.5)

42.3 (6.1)

1.7 (0.4)

1.1 (0.4)

−0.6 (−1.7, 0.5)

 LVEDV (ml)

253

99.9 (33.9)

98.0 (26.4)

0.08 (1.7)

−2.0 (1.5)

−2.1 (−6.6, 2.4)

 LVESD (mm)

233

34.0 (6.5)

34.3 (5.1)

1.3 (0.5)

−0.3 (0.4)

−1.5 (−2.8, −0.3)

 LVESV (ml)

253

45.1 (26.9)

43.8 (22.2)

6.9 (1.4)

3.9 (1.1)

−3.0 (−6.5, 0.5)

 LV mass index (g m−2)

255

173.2 (39.2)

175.3 (39.3)

19.9 (3.6)

18.6 (3.2)

−1.3 (−10.8, 8.3)

LV systolic function

 LVEF (%)

253

56.3 (12.8)

56.9 (12.8)

−6.4 (0.9)

−4.8 (0.8)

1.5 (−0.9, 4.0)

 Absolute GLS (%)

259

13.5 (3.4)

13.9 (3.5)

−1.9 (0.3)

−0.8 (0.2)

1.1 (0.4, 1.8)

 Stroke volume (ml)

243

50.7 (17.8)

50.0 (15.5)

−6.3 (1.1)

−2.6 (1.3)

3.7 (0.4, 7.1)

 TDI lateral s’ (mm s−1)

246

48.9 (16.8)

48.7 (14.5)

2.9 (1.4)

5.0 (1.5)

2.2 (−1.9, 6.3)

 TDI septal s’ (mm s−1)

247

41.6 (11.1)

41.4 (11.7)

1.1 (1.0)

2.6 (1.0)

1.5 (−1.3, 4.3)

LV diastolic function

 E/A ratio

151

2.1 (1.1)

2.2 (1.1)

0.2 (0.1)

0.1 (0.1)

−0.1 (−0.5, 0.3)

 E wave (mm s−1)

257

813.0 (221.1)

789.0 (189.3)

38.4 (16.8)

39.0 (14.4)

0.5 (−43.2, 44.2)

 A wave (mm s−1)

152

457.0 (217.8)

425.6 (189.3)

−18.9 (21.6)

−3.0 (23.6)

15.9 (−47.5, 79.3)

 Deceleration time (ms)

252

224.3 (60.0)

221.2 (61.0)

−28.3 (4.5)

−36.7 (3.8)

−8.4 (−20.0, 3.2)

 TDI lateral e’ (mm s−1)

247

58.9 (21.5)

61.7 (22.7)

5.9 (1.7)

6.6 (1.7)

0.7 (−4.1, 5.5)

 TDI septal e’ (mm s−1)

249

39.9 (11.2)

43.4 (14.8)

3.1 (1.1)

5.0 (1.2)

1.9 (−1.3, 5.0)

 E/e’ lateral

246

15.4 (7.2)

14.4 (6.1)

−0.6 (0.5)

−1.1 (0.4)

−0.5 (−1.7, 0.7)

 E/e’ septal

248

21.9 (10.1)

20.0 (7.8)

−0.2 (0.6)

−1.3 (0.5)

−1.1 (−2.6, 0.5)

 E/e’ average

245

18.4 (6.8)

17.2 (6.3)

−0.4 (0.5)

−1.2 (0.4)

−0.8 (−1.9, 0.4)

LA size and function

 LA diameter (mm)

254

41.9 (5.3)

41.2 (5.4)

0.9 (0.4)

0.3 (0.4)

−0.6 (−1.7, 0.6)

 LA volume index (ml m−2)

255

38.0 (11.5)

36.9 (9.8)

6.2 (0.9)

5.2 (0.7)

−1.0 (−3.3, 1.3)

 TDI lateral a’ (mm s−1)

161

42.5 (21.7)

39.7 (19.0)

1.8 (2.0)

3.0 (2.2)

1.1 (−4.7, 7.0)

 TDI septal a’ (mm s−1)

142

39.1 (19.2)

36.6 (15.4)

0.1 (2.0)

−2.6 (1.9)

−2.6 (−8.2, 3.0)

RV and pulmonary pressure

 RV free wall thickness (mm)

174

7.7 (0.2)

7.5 (0.2)

1.9 (0.2)

1.7 (0.2)

−0.3 (−0.9, 0.4)

 RV end-diastolic area (cm2)

233

23.5 (7.1)

21.6 (5.1)

−0.4 (0.5)

−0.9 (0.5)

−0.5 (−1.9, 1.0)

 RV end-systolic area (cm2)

232

14.3 (5.4)

12.7 (3.6)

1.6 (0.4)

1.8 (0.4)

0.2 (−0.9, 1.3)

 RV S’ (mm s−1)

251

91.4 (25.6)

95.0 (24.4)

−4.0 (2.4)

2.8 (2.3)

6.8 (0.3, 13.3)

 TR velocity (m s−1)

227

2.6 (0.4)

2.6 (0.5)

−0.2 (0.0)

−0.2 (0.0)

−0.0 (−0.1, 0.1)

 Maximal IVC diameter (mm)

197

20.4 (5.9)

20.2 (5.1)

0.6 (0.5)

−0.2 (0.5)

−0.8 (−2.3, 0.7)

  1. Results are reported as the LS mean difference (s.e.m.) derived from repeated measures models with baseline as a covariate and fixed-effect terms including the treatment group, visit, treatment-by-visit interaction, type of ATTR amyloidosis and age group. The overall population also included baseline tafamidis use and treatment-by-baseline tafamidis use interaction as fixed-effect terms.
Back to article page